Pipeline
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3
MRNA
FY2026 Q2
예상 부합
Moderna, Inc. 실적 발표
Buzzberg 분석
Norovirus phase 3 interim misses early success; fourth cohort to enroll
Moderna's Q2 2026 call was a steady-state update: the company beat quarterly revenue expectations, maintained its full-year guidance, and reduced cost forecasts. Major pipeline milestones remain the primary focus, with the crucial Phase 3 melanoma data for intesmorum expected in the second half of the year. Reported Q2 2026 revenue of $145M, beating the guidance range.
Buzzberg 분석 Norovirus phase 3 interim misses early success; fourth cohort to enroll Moderna's Q2 2026 call was a steady-state update: the company beat quarterly revenue expectations, maintained its full-year guidance, and reduced cost forecasts. Major pipeline milestones remain the primary focus, with the crucial Phase 3 melanoma data for intesmorum expected in the second half of the year. Reported Q2 2026 revenue of $145M, beating the guidance range. 전체 분석 보기분석 접기
Moderna's Q2 2026 call was a steady-state update: the company beat quarterly revenue expectations, maintained its full-year guidance, and reduced cost forecasts. Major pipeline milestones remain the primary focus, with the crucial Phase 3 melanoma data for intesmorum expected in the second half of the year. Reported Q2 2026 revenue of $145M, beating the guidance range.
- Reiterated full-year 2026 revenue growth guidance of up to 10%.
- Lowered 2026 operating expense and cash cost guidance by $0.2B.
- Flu vaccine (mRNA-1010) received a positive unanimous VRBPAC recommendation, ahead of an August 5th PDUFA date.
매출$0.145B보고값
주당순이익(EPS)$-1.97+42% 전분기 대비
매출총이익률35.86%보고값
잉여현금흐름$-0.563B+19% 전분기 대비
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Pipeline
INT melanoma phase 3 interim analysis expected in second half 2026
Regulatory
Flu vaccine receives unanimous VRBPAC recommendation; PDUFA August 5
핵심 내용 3개 더 보기
Guidance
2026 cash cost guidance improved by $200 million to about $4 billion
Competitive Position
mRNA-1010 flu vaccine could enable late strain selection for 2027
Pipeline
RCC INT study could read out this year or next depending on events
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $0.145B | 보고값 |
| 주당순이익(EPS) | $-1.97 | +42% 전분기 대비 |
| 매출총이익률 | 35.86% | 보고값 |
| 잉여현금흐름 | $-0.563B | +19% 전분기 대비 |
| 자본지출 | $0.037B | 보고값 |
| 순이익 | $-0.782B | +42% 전분기 대비 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2026 | $0.2B–$0.3B | $0.25B | 유지 |
| 영업이익률 | FY2026 | $4.7B | $4.7B | 하향 |
AI, 자본지출 및 수요 분석
경영진 분석
Measured Optimism
Management conveyed confidence in execution and pipeline progress while acknowledging misses (norovirus interim) and maintaining disciplined financial guidance.
투자 및 생산능력
Capital expenditures are still projected to be between $0.2 and $0.3 billion for 2026, with no change from prior guidance. The focus remains on operational efficiency and reducing cash costs rather than new capacity investments, though the company has established manufacturing capacity for a potential INT launch.
아래에 언급된 기업 3개 모두 표시
기업발표 이후 수익률
파트너
파트너
Stéphane Bancel
Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches. — A late strain update capability could allow Moderna to offer a better-matched vaccine in a given season, potentially shifting market share from incumbent flu vaccine makers.
근거
“And so, as you can imagine, Moderna and their Merck colleagues have been very active Stephen talked about manufacturing a minute ago, but they've been very active on the commercial side of the house in terms of medical affairs, marketing,”
공급망
공급망
Stephen Hoge
Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches. — A late strain update capability could allow Moderna to offer a better-matched vaccine in a given season, potentially shifting market share from incumbent flu vaccine makers.
근거
“Our demonstrated capability in the COVID context is less than two months, and so strain selections have happened as late as early July in the history of COVID and we've been able to make a fall vaccination season work with millions of”
공급망
Stéphane Bancel
Moderna indicates that Europe will become a major growth driver starting in 2027, as an exclusive EU partnership from the pandemic era potentially expires, opening the door for their products. — Entry into the European market for COVID/flu vaccines would directly challenge incumbents Sanofi and GSK in a major market.
근거
“So we really see Europe as a very important growth driver for us.”
외부 신호
공급망 알파 · 3발표 이후 수익률
Moderna's flu vaccine (mRNA-1010) has the capability to update its strain selection in under two months, a potential flexibility advantage over incumbent flu vaccines in response to late-season strain mismatches.
근거
“Our demonstrated capability in the COVID context is less than two months, and so strain selections have happened as late as early July in the history of COVID and we've been able to make a fall vaccination season work with millions of dose…”
Moderna indicates that Europe will become a major growth driver starting in 2027, as an exclusive EU partnership from the pandemic era potentially expires, opening the door for their products.
Revenue growth for 2026 is largely pre-contracted, with the biggest U.S. variable being whether vaccination rate declines meet projections; any upside from a milder decline appears to flow directly to the top line.
근거
“The biggest upside swing is if it is not as big a decline as we've projected, then we should have upside in the U.S.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 3개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.